info@mail.ucallm.com
Comprehensive ferroptosis research requires integrated analysis of iron metabolism, phospholipid remodeling, antioxidant defense systems, mitochondrial function, and immune regulation to elucidate ferroptotic mechanisms and identify therapeutic vulnerabilities across cancer, neurodegeneration, and inflammatory diseases.
We provide a comprehensive research platform — from ferroptosis regulatory targets to functional cell death assays — enabling precise investigation of ferroptotic mechanisms.
Key Target Highlights
Core Molecular Targets in Ferroptosis Research
Biological Process | Key Targets | Biological Significance | Research Applications |
Iron metabolism | TFRC, FTH1, FTL, NCOA4, FPN1 | Regulates intracellular iron availability | Cancer, AKI, liver injury |
Lipid remodeling | ACSL4, LPCAT3 | Generates ferroptosis-sensitive phospholipids | Tumor metabolism |
Lipid peroxidation | ALOX15, POR | Catalyzes phospholipid oxidation | Oxidative injury |
Antioxidant defense | SLC7A11 (xCT), GPX4, GSH | Primary ferroptosis suppression system | Drug mechanism studies |
Alternative defense | FSP1 (AIFM2), CoQ10 | GPX4-independent protection | Ferroptosis resistance |
Mitochondrial metabolism | DHODH | Mitochondrial antioxidant pathway | Cancer metabolism |
Radical trapping pathway | GCH1, BH4 | Prevents phospholipid oxidation | Novel therapeutic targets |
Stress adaptation | NRF2, KEAP1, HO-1 | Coordinates antioxidant response | Oxidative stress biology |
Key research trend:
Modern ferroptosis research is rapidly evolving from the classical System Xc⁻–GSH–GPX4 model toward an integrated regulatory network encompassing iron homeostasis, phospholipid remodeling, mitochondrial metabolism, alternative antioxidant systems (FSP1–CoQ10, DHODH, GCH1–BH4), immune regulation, and spatial multi-omics. Recent consensus guidelines further emphasize standardized experimental validation and reproducibility, while emerging therapeutic strategies increasingly exploit ferroptosis vulnerabilities in cancer, neurodegeneration, and inflammatory diseases.
Recommended Ferroptosis Marker Strategy
Multi-Level Validation Framework
Detection Layer | Representative Markers | Scientific Purpose |
Iron Homeostasis | TFRC, Ferritin (FTH1), NCOA4 | Assess intracellular iron regulation |
Lipid Peroxidation | 4-HNE, MDA, C11-BODIPY oxidation | Confirm membrane lipid oxidation |
Core Ferroptosis Machinery | GPX4, SLC7A11, GSH | Evaluate antioxidant defense |
Lipid Metabolism | ACSL4, LPCAT3, ALOX15 | Determine ferroptosis susceptibility |
Alternative Defense Systems | FSP1, DHODH, GCH1 | Investigate ferroptosis resistance mechanisms |
Oxidative Stress | NRF2, HO-1, ROS | Characterize cellular stress responses |
Mitochondrial Function | TOM20, COX IV, mitochondrial ROS | Assess mitochondrial contribution |
Core Ferroptosis Validation Strategy
"Golden Pair" Concept for Pathway Confirmation
Strategy | Marker Combination | Scientific Purpose | Application |
Golden Pair A: Core Ferroptosis | GPX4 + Lipid Peroxidation (C11-BODIPY/4-HNE) | Confirm canonical ferroptosis | Cell death studies |
Golden Pair B: Iron Dependency | TFRC + Ferritin/NCOA4 | Verify iron-dependent regulation | Iron metabolism research |
Golden Pair C: Lipid Remodeling | ACSL4 + LPCAT3 | Evaluate membrane susceptibility | Tumor ferroptosis |
Golden Pair D: Resistance Mechanisms | GPX4 + FSP1 (or DHODH) | Distinguish parallel antioxidant systems | Drug resistance studies |
Competitive Technology Landscape
Ferroptosis Research Workflow
Ferroptosis research requires a multi-dimensional validation strategy integrating cell death assessment, lipid peroxidation detection, molecular pathway analysis, metabolic profiling, and functional screening. A comprehensive workflow enables researchers to accurately define ferroptotic mechanisms, identify regulatory networks, and discover potential therapeutic targets.
Pathway Overview
Ferroptosis is an iron-dependent regulated cell death pathway characterized by iron accumulation, lipid peroxidation, and failure of antioxidant defense systems. Key regulators include the GPX4–glutathione axis, system Xc⁻, ACSL4, iron metabolism pathways, and lipid remodeling enzymes. Ferroptosis research provides new insights into cancer therapy, neurodegeneration, immunity, and metabolic diseases.
Cancer-related pathways in ferroptosis. (PMID: 38453898)
Recommended Experimental Validation Workflow
Step | Experimental Goal | Representative Readouts |
Step 1 | Establish ferroptosis model | Erastin, RSL3, cystine deprivation, GPX4 inhibition |
Step 2 | Confirm iron accumulation | TFRC, ferritin, Fe²⁺ assays |
Step 3 | Verify lipid peroxidation | C11-BODIPY, 4-HNE, MDA |
Step 4 | Analyze antioxidant defense | GPX4, SLC7A11, GSH |
Step 5 | Investigate resistance pathways | FSP1, DHODH, GCH1, NRF2 |
Featured Research Application Examples
Research Area | Model System | Key Evaluation Parameters | Scientific Question |
Cancer ferroptosis | Solid tumor cell lines | GPX4, ACSL4, lipid ROS | Can ferroptosis improve cancer therapy? |
Neurodegeneration | Neuronal cultures, animal models | Iron metabolism, GPX4 | Does ferroptosis contribute to neuronal loss? |
Acute kidney injury (AKI) | Renal injury models | GPX4, lipid oxidation, iron markers | Is ferroptosis a driver of kidney injury? |
Ischemia-reperfusion injury | Cardiac/hepatic/brain IRI models | ROS, lipid peroxidation, NRF2 | How does ferroptosis mediate tissue damage? |
Immuno-oncology | Tumor–immune co-culture | IFN-γ, SLC7A11, GPX4 | How do immune cells induce ferroptosis? |
Frequently Asked Questions
Q1. Which markers are recommended to confirm ferroptosis activation?
Ferroptosis validation requires multiple complementary markers because no single biomarker is sufficient. Common ferroptosis markers include GPX4 and SLC7A11/xCT for antioxidant defense, ACSL4 for lipid remodeling and ferroptosis sensitivity, FTH1/FTL and TFRC for iron metabolism, and 4-HNE/MDA or lipid ROS detection for lipid peroxidation. Reliable studies should combine molecular marker analysis with functional validation using ferroptosis inhibitors such as Ferrostatin-1 or Liproxstatin-1.
Q2. How can ferroptosis be distinguished from other forms of regulated cell death?
Ferroptosis is characterized by iron-dependent lipid peroxidation rather than caspase activation or membrane rupture. Researchers should combine ferroptosis markers (GPX4, SLC7A11, ACSL4, lipid ROS) with exclusion markers for other pathways, such as cleaved Caspase-3/PARP for apoptosis and RIPK1/RIPK3/MLKL for necroptosis. Pharmacological rescue experiments provide additional confirmation of ferroptosis specificity.
Q3.What are the major signaling pathways involved in ferroptosis regulation?
Key ferroptosis regulatory networks include the SLC7A11–GSH–GPX4 axis, which controls lipid peroxide detoxification; iron metabolism pathways involving TFRC, FTH1, FTL, and NCOA4-mediated ferritinophagy; and lipid metabolism pathways regulated by ACSL4 and LPCAT3. Stress-responsive pathways such as NRF2, p53, AMPK, and mTOR further regulate ferroptosis sensitivity.
Q4.What are the common challenges in ferroptosis research?
Major challenges include overinterpreting ROS accumulation, relying on a single marker, and failing to distinguish ferroptosis from other cell death mechanisms. Best practices include using multiple biomarkers, appropriate positive controls (e.g., Erastin, RSL3), ferroptosis inhibitors, and genetic approaches targeting key regulators such as GPX4, SLC7A11, or ACSL4.
Q5.How can ferroptosis research contribute to disease mechanism and therapeutic discovery?
Ferroptosis plays important roles in cancer, immunity, neurodegeneration, aging, and metabolic diseases. Integrating ferroptosis marker analysis with multi-omics, lipidomics, and functional assays enables identification of disease-associated mechanisms, therapeutic targets, and potential precision medicine strategies.
Key References
1. Jiang X., Stockwell B.R., Conrad M. (2021). Ferroptosis: mechanisms, biology and role in disease. Nature Reviews Molecular Cell Biology. 22:266–282.
2. Tang D., Chen X., Kang R., Kroemer G. (2021). Ferroptosis: molecular mechanisms and health implications. Cell Research. 31:107–125.
3. Stockwell B.R. (2022). Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 185:2401–2421.
4. Bersuker K., Hendricks J.M., Li Z., et al. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 575:688–692.
5. Doll S., Freitas F.P., Shah R., et al. (2019). FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 575:693–698.
6. Jiang L., Kon N., Li T., et al. (2015). Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 520:57–62.
7. Dixon S.J., Lemberg K.M., Lamprecht M.R., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 149:1060–1072.
8. Gao M., Monian P., Quadri N., et al. (2015). Glutaminolysis and transferrin regulate ferroptosis. Molecular Cell. 59:298–308.